Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores.
about
Porous Polymersomes with Encapsulated Gd-labeled Dendrimers as Highly Efficient MRI Contrast Agents.Synthesis and evaluation of globular Gd-DOTA-monoamide conjugates with precisely controlled nanosizes for magnetic resonance angiographyMacromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.Poly(amidoamine) dendrimer based MRI contrast agents exhibiting enhanced relaxivities derived via metal preligation techniques.Comparison of MRI properties between derivatized DTPA and DOTA gadolinium-dendrimer conjugates.Macromolecular and dendrimer-based magnetic resonance contrast agents.PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approachParamagnetic liposomes for molecular MRI and MRI-guided drug delivery.Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI.Biologically optimized nanosized molecules and particles: more than just size.Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiographyICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance.Strategies for the preparation of bifunctional gadolinium(III) chelators.Dendrimer-entrapped gold nanoparticles as potential CT contrast agents for blood pool imagingPeptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review.Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy.Biodegradable polydisulfide dendrimer nanoclusters as MRI contrast agents.Cellular magnetic resonance imaging: current status and future prospects.Gadolinium-based contrast agents for magnetic resonance cancer imaging.Gadolinium(III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential.Emerging nanomedicine opportunities with perfluorocarbon nanoparticles.N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.Tumour and dendrimers: a review on drug delivery aspects.Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery.Targeting Glioma with a Dual Mode Optical and Paramagnetic Nanoprobe across the Blood-brain Tumor BarrierEfficient GSH delivery using PAMAM-GSH into MPP-induced PC12 cellular model for Parkinson's disease.Effects of nanomaterial physicochemical properties on in vivo toxicity.Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis.Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: reference to pharmacokinetic properties of dendrimer-based MR contrast agents.Application of Dendrimer-based Nanoparticles in Glioma Imaging.A scale to measure MRI contrast agent sensitivity.In Vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent.Preparation of intravenous injection nanoformulation via co-assemble between cholesterylated gemcitabine and cholesterylated mPEG: enhanced cellular uptake and intracellular drug controlled release.Quantitative determination of poly(amidoamine) dendrimers in urine by liquid chromatography/electrospray ionization hybrid quadrupole linear ion trap mass spectrometry.
P2860
Q30584790-730EDDD0-900D-4A72-A80D-DC385A5C8C8DQ33570993-2713D979-9CFE-4E89-9CA0-43A662D2922FQ33847006-49A576FB-5D24-415F-9BC3-B5625D22EA9AQ33927446-5372CD82-47F8-4ABD-A526-A83679E55643Q34054331-2953B130-311E-454D-BA79-17C2F04D31BFQ34069230-4EF9D7AC-4F98-4586-B31D-8E8FA6492D4FQ34165944-CF937B6C-81DF-4004-87E8-5AF4B2D36D3EQ34736942-14E7F76A-9C15-4072-8598-0CA2B3F90571Q34850437-D46D5FBE-E7F3-4119-A818-B798234438CFQ35048175-28708F7E-1031-4CC4-AEEC-7B117080C548Q35605967-56581A8C-BA8C-494B-8680-31A29812AE9AQ35612858-BE0DA9CD-0A39-4164-AD7E-B5667F7E3110Q35777941-4E24F080-A0BC-4FB4-AC6E-ADC577970070Q35881174-2943E6D7-7BF2-492F-AADA-2A2095CAEEDAQ35997103-6FA64914-7915-406A-879B-44C7D134074CQ36125194-22092A26-59FF-4619-9D48-9BF1BCF761B7Q36216849-DD0B6414-8B5C-4E5E-9E39-D4388F9F4B8BQ36429106-294A35D4-777B-4E30-8024-E726E577FB88Q36546298-A6638A41-DC07-44FA-90E1-A768B7283C50Q36555415-94748FBC-E46C-4C80-9A62-AB2D1FB8F586Q36750157-5408AFF9-D52A-4305-8782-9864A64D0282Q36759502-84F84F99-6867-4F60-A94F-AA7DC231F4CCQ37087186-9DABA2E3-4DAA-46A1-A9BA-8B4DF24C92A8Q37171165-57682AAB-EFF8-4982-AAB9-53C570E1A723Q37216165-22C335C4-27F2-41A9-BCE2-AF35D2DF032AQ37296161-6459D399-CD6F-4A98-BF3E-B2C8461BCCCAQ37298397-B5A5F51D-9AAE-4C49-A037-D4AB8F541ADDQ37345372-4527A229-1D04-425E-959E-DABEA127C9EAQ38090392-B204B562-42B5-4916-9DD9-95AC9BA21122Q38539866-AAE0F2B3-79E0-43B0-A462-3069A6A35BDFQ38844101-82E5BCE1-CDA9-443D-9A86-819F07740FABQ40762794-5CE153B1-4469-436B-9948-370960A4FD2BQ41533358-02B82591-EB77-4D9F-BC00-4E5BD9A0FB11Q43496696-0C35901F-F446-483D-8881-9F3EECA238E6Q44278063-DCED12B9-767E-4964-BBD0-FE79ED0865FAQ50930245-9D43E0F2-44EE-4C59-981A-17FAA3195D91Q54765569-68A967B1-D580-4FF7-B8B6-12DA8D6EB9C4
P2860
Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@en
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@nl
type
label
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@en
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@nl
prefLabel
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@en
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and enhanceme ...... olyamidoamine dendrimer cores.
@en
P2093
H Kobayashi
M W Brechbiel
P2860
P304
P356
10.1002/MRM.1314
P577
2001-12-01T00:00:00Z